Big Pharmas slash cancer drug prices again for Chinese insurance by Angus Liu Wednesday, October 10, 2018 Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
Boehringer quits on Gilotrif expansion effort in head and neck cancer by Carly Helfand Monday, July 25, 2016 Boehringer was hoping to get some more mileage out of targeted lung cancer med Gilotrif. But those hopes have been dashed by a data monitoring committee.
